{"id":260586,"date":"2020-07-06T02:13:49","date_gmt":"2020-07-06T06:13:49","guid":{"rendered":"https:\/\/canadianinquirer.net\/v1\/?p=260586"},"modified":"2020-07-06T02:13:49","modified_gmt":"2020-07-06T06:13:49","slug":"who-suspends-hydroxychloroquine-trial-for-second-time","status":"publish","type":"post","link":"https:\/\/canadianinquirer.net\/v1\/2020\/07\/06\/who-suspends-hydroxychloroquine-trial-for-second-time\/","title":{"rendered":"WHO suspends hydroxychloroquine trial for second time"},"content":{"rendered":"<figure id=\"attachment_211991\" aria-describedby=\"caption-attachment-211991\" style=\"width: 4000px\" class=\"wp-caption alignnone\"><a href=\"https:\/\/canadianinquirer.net\/v1\/wp-content\/uploads\/2019\/04\/adult-aging-bottle-1389104.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-211991\" src=\"https:\/\/canadianinquirer.net\/v1\/wp-content\/uploads\/2019\/04\/adult-aging-bottle-1389104.jpg\" alt=\"\" width=\"4000\" height=\"2667\" srcset=\"https:\/\/canadianinquirer.net\/v1\/wp-content\/uploads\/2019\/04\/adult-aging-bottle-1389104.jpg 4000w, https:\/\/canadianinquirer.net\/v1\/wp-content\/uploads\/2019\/04\/adult-aging-bottle-1389104-300x200.jpg 300w, https:\/\/canadianinquirer.net\/v1\/wp-content\/uploads\/2019\/04\/adult-aging-bottle-1389104-768x512.jpg 768w, https:\/\/canadianinquirer.net\/v1\/wp-content\/uploads\/2019\/04\/adult-aging-bottle-1389104-1024x683.jpg 1024w\" sizes=\"auto, (max-width: 4000px) 100vw, 4000px\" \/><\/a><figcaption id=\"caption-attachment-211991\" class=\"wp-caption-text\">\u201cWHO today accepted the recommendation from the Solidarity Trial\u2019s International Steering Committee to discontinue the trial\u2019s hydroxychloroquine and lopinavir\/ritonavir arms,\u201d the WHO said in a statement. \u201cThe Solidarity Trial was established by WHO to find an effective Covid-19 treatment for hospitalized patients.\u201d (Pexels photo)<\/figcaption><\/figure>\n<p><strong>GENEVA<\/strong>\u00a0\u2013 The World Health Organization (WHO) on Saturday said it stopped a clinical trial of the anti-malaria drug hydroxychloroquine to treat coronavirus disease 2019 (Covid-19) patients.<\/p>\n<p>\u201cWHO today accepted the recommendation from the Solidarity Trial\u2019s International Steering Committee to discontinue the trial\u2019s hydroxychloroquine and lopinavir\/ritonavir arms,\u201d the WHO said in a statement. \u201cThe Solidarity Trial was established by WHO to find an effective Covid-19 treatment for hospitalized patients.\u201d<\/p>\n<p>The organization said that according to interim trial results, \u201chydroxychloroquine and lopinavir\/ritonavir produce little or no reduction in the mortality of hospitalized Covid-19 patients when compared to standard of care. Solidarity trial investigators will interrupt the trials with immediate effect.\u201d<\/p>\n<p>In May, the WHO said that due to safety concerns, it was temporarily halting a clinical trial of hydroxychloroquine for Covid-19 patients.<\/p>\n<p>Since first appearing in Wuhan, China last December, the coronavirus disease has spread to at least 188 countries and regions.<\/p>\n<p>The US, Brazil and Russia are currently the countries hardest hit in the world.<\/p>\n<p>The pandemic has killed more than 528,200 people worldwide, with an excess of 11.1 million confirmed cases and greater than 6 million recoveries, according to figures compiled by US-based Johns Hopkins University.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>GENEVA\u00a0\u2013 The World Health Organization (WHO) on Saturday said it stopped a clinical trial of the anti-malaria drug hydroxychloroquine to &hellip;<\/p>\n","protected":false},"author":33,"featured_media":211991,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16,17],"tags":[],"class_list":["post-260586","post","type-post","status-publish","format-standard","has-post-thumbnail","category-news","category-news-w","mauthors-anadolu","mauthors-philippine-news-agency"],"_links":{"self":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts\/260586","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/users\/33"}],"replies":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/comments?post=260586"}],"version-history":[{"count":2,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts\/260586\/revisions"}],"predecessor-version":[{"id":260588,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts\/260586\/revisions\/260588"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/media\/211991"}],"wp:attachment":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/media?parent=260586"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/categories?post=260586"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/tags?post=260586"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}